Eylea 2 mg (Aflibercept SOLUTION) 2 MG

Aflibercept, the active ingredient in Eylea 2 mg, works by binding to vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF). By binding to these factors, Aflibercept prevents the activation of VEGF receptors, thereby inhibiting the growth of new blood vessels. This mechanism helps to reduce abnormal blood vessel growth and leakage in the retina, which is crucial in treating various eye conditions.

The dosage of Eylea 2 mg is determined by a healthcare professional based on the patient's condition and response to treatment. It is typically administered as an intravitreal injection, and the frequency of injections is adjusted according to the patient's needs. Always follow the prescribed dosage and administration instructions provided by your healthcare provider.

The safety of Eylea 2 mg during pregnancy and breastfeeding has not been established. It is important to discuss the potential risks and benefits with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. Your healthcare provider can help you make an informed decision based on your specific situation.

To order Eylea 2 mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

Eylea 2 mg is one of several treatments available for macular degeneration. It is a VEGF inhibitor that works by reducing the growth of abnormal blood vessels in the retina. Compared to other treatments, Eylea 2 mg has been shown to be effective in improving or maintaining vision in patients with neovascular age-related macular degeneration. Your healthcare provider can help you determine the best treatment option based on your specific condition and needs.

Eylea 2 mg should be stored at 2-8°C, kept refrigerated, and protected from light. It is important not to freeze or shake the medication. Always follow the storage and handling instructions provided by your healthcare provider or the product packaging to ensure the medication remains effective and safe to use.

Eylea 2 mg is administered as an intravitreal injection, which means it is injected directly into the vitreous humor of the eye. This procedure is typically performed by a healthcare professional in a clinical setting. The injection is usually well-tolerated, but some patients may experience mild discomfort or side effects such as eye pain or redness at the injection site.

While Eylea 2 mg is generally well-tolerated, there are some serious risks to be aware of. These include endophthalmitis (severe eye infection), retinal detachment, and increased risk of arterial thromboembolic events such as heart attack or stroke. It is important to monitor for any signs of these serious side effects and to seek immediate medical attention if they occur.

Eylea 2 mg should not be used by individuals who have a known hypersensitivity to Aflibercept or any of the excipients in the medication. It is also important to discuss your medical history with your healthcare provider, including any pre-existing eye conditions, infections, or other health issues, to determine if Eylea 2 mg is suitable for you. Always follow the advice of your healthcare provider regarding the use of this medication.